Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$12.13
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
NeuroPace Analyst Ratings and Price Targets | NASDAQ:NPCE | Benzinga
NeuroPace Inc has a consensus price target of $15.6 based on the ratings of 10 analysts. The high is $22 issued by Leerink Partners on January 30, 2024. The low is $8 issued by Morgan Stanley on July 15, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Wells Fargo, and UBS on March 5, 2025, January 30, 2025, and January 21, 2025, respectively. With an average price target of $18 between Cantor Fitzgerald, Wells Fargo, and UBS, there's an implied 48.39% upside for NeuroPace Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Wells Fargo
UBS
JP Morgan
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for NeuroPace
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/05/2025 | Buy Now | 64.88% | Cantor Fitzgerald | Ross Osborn51% | $19 → $20 | Maintains | Overweight | Get Alert |
| 01/30/2025 | Buy Now | 40.15% | Wells Fargo | Larry Biegelsen69% | $13 → $17 | Maintains | Overweight | Get Alert |
| 01/21/2025 | Buy Now | 40.15% | UBS | Priya Sachdeva29% | → $17 | Initiates | → Buy | Get Alert |
| 12/17/2024 | Buy Now | 15.42% | JP Morgan | Robbie Marcus67% | $9 → $14 | Maintains | Overweight | Get Alert |
| 11/13/2024 | Buy Now | 7.17% | Wells Fargo | Vik Chopra42% | $15 → $13 | Maintains | Overweight | Get Alert |
| 08/14/2024 | Buy Now | 48.39% | Cantor Fitzgerald | Ross Osborn51% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2024 | Buy Now | 23.66% | Wells Fargo | Vik Chopra42% | $20 → $15 | Maintains | Overweight | Get Alert |
| 07/15/2024 | Buy Now | -34.05% | Morgan Stanley | Drew Ranieri45% | $9.5 → $8 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 48.39% | Cantor Fitzgerald | Ross Osborn51% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 03/14/2024 | Buy Now | 64.88% | Wells Fargo | Lawrence Biegelsen41% | $16 → $20 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/12/2024 | Buy Now | 40.15% | JP Morgan | Robbie Marcus67% | $9 → $17 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 48.39% | Cantor Fitzgerald | Ross Osborn51% | $16 → $18 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 7.17% | Morgan Stanley | Drew Ranieri45% | $9 → $13 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 31.9% | Wells Fargo | Lawrence Biegelsen41% | $9 → $16 | Maintains | Equal-Weight | Get Alert |
| 01/30/2024 | Buy Now | 81.37% | Leerink Partners | Mike Kratky66% | → $22 | Initiates | → Outperform | Get Alert |
| 12/27/2023 | Buy Now | -1.07% | Lake Street | Frank Takkinen40% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | Buy Now | -25.8% | Morgan Stanley | Drew Ranieri45% | $8 → $9 | Maintains | Equal-Weight | Get Alert |
| 11/14/2023 | Buy Now | -34.05% | Morgan Stanley | Drew Ranieri45% | $6 → $8 | Maintains | Equal-Weight | Get Alert |
| 11/10/2023 | Buy Now | -9.32% | Cantor Fitzgerald | Ross Osborn51% | → $11 | Initiates | → Overweight | Get Alert |
| 11/07/2023 | Buy Now | -25.8% | JP Morgan | Robbie Marcus67% | $6 → $9 | Maintains | Overweight | Get Alert |
| 10/04/2023 | Buy Now | -25.8% | Wells Fargo | Lawrence Biegelsen41% | $6 → $9 | Maintains | Equal-Weight | Get Alert |
| 08/24/2023 | Buy Now | -50.54% | Morgan Stanley | Drew Ranieri45% | $5 → $6 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | -58.78% | Morgan Stanley | Drew Ranieri45% | $4.5 → $5 | Maintains | Underweight | Get Alert |
| 03/03/2023 | Buy Now | -62.9% | Morgan Stanley | Drew Ranieri45% | $2.5 → $4.5 | Maintains | Underweight | Get Alert |
| 02/22/2023 | Buy Now | -17.56% | Lake Street | Frank Takkinen40% | → $10 | Initiates | → Buy | Get Alert |
| 01/06/2023 | Buy Now | -79.39% | Morgan Stanley | Drew Ranieri45% | $3.5 → $2.5 | Maintains | Underweight | Get Alert |
| 10/11/2022 | Buy Now | -71.15% | Morgan Stanley | Drew Ranieri45% | $5.5 → $3.5 | Maintains | Underweight | Get Alert |
| 07/15/2022 | Buy Now | -54.66% | Morgan Stanley | Drew Ranieri45% | $6 → $5.5 | Maintains | Underweight | Get Alert |
| 05/13/2022 | Buy Now | -50.54% | Morgan Stanley | Drew Ranieri45% | $9 → $6 | Maintains | Underweight | Get Alert |
| 05/13/2022 | Buy Now | -50.54% | Wells Fargo | Lawrence Biegelsen41% | $9 → $6 | Maintains | Equal-Weight | Get Alert |
| 04/06/2022 | Buy Now | 7.17% | Wolfe Research | Mike Polark55% | → $13 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for NeuroPace (NPCE) stock?
The latest price target for NeuroPace (NASDAQ:NPCE) was reported by Cantor Fitzgerald on March 5, 2025. The analyst firm set a price target for $20.00 expecting NPCE to rise to within 12 months (a possible 64.88% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeuroPace (NPCE)?
The latest analyst rating for NeuroPace (NASDAQ:NPCE) was provided by Cantor Fitzgerald, and NeuroPace maintained their overweight rating.
When was the last upgrade for NeuroPace (NPCE)?
The last upgrade for NeuroPace Inc happened on March 14, 2024 when Wells Fargo raised their price target to $20. Wells Fargo previously had an equal-weight for NeuroPace Inc.
When was the last downgrade for NeuroPace (NPCE)?
There is no last downgrade for NeuroPace.
When is the next analyst rating going to be posted or updated for NeuroPace (NPCE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroPace, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroPace was filed on March 5, 2025 so you should expect the next rating to be made available sometime around March 5, 2026.
Is the Analyst Rating NeuroPace (NPCE) correct?
While ratings are subjective and will change, the latest NeuroPace (NPCE) rating was a maintained with a price target of $19.00 to $20.00. The current price NeuroPace (NPCE) is trading at is $12.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.